



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

NOV 26 1999

Mr. John Jabara
Vice President and Director
Vaccines Business Unit, U.S.
SmithKline Beecham Pharmaceuticals
One Franklin Plaza
P.O. Box 7929
Philadelphia, Pennsylvania 19101

Dear Mr. Jabara:

I am responding to your letters to Mr. Kevin Thurm, Deputy Secretary to the Department of Health and Human Services (HHS), Dr. David Satcher, Assistant Secretary for Health and Surgeon General (HHS), and to me concerning SmithKline Beecham (SKB) Pharmaceuticals' increased inventories of a thimerosal-free Diphtheria and Tetanus Toxoid and Acellular Pertussis Vaccine (DTaP), which are capable of meeting domestic market needs through the first half of calendar year 2000.

The Centers for Disease Control and Prevention's (CDC) National Immunization Program staff has communicated this updated information regarding your supply to the 64 immunization projects. CDC also plans to monitor DTaP ordering patterns and continue to provide the States with a choice among currently licensed brands of DTaP vaccine.

CDC appreciates the contributions of SKB Pharmaceuticals and other vaccine manufacturers in our Nation's ongoing efforts to effectively and safely reach the immunization goals for our children and youth.

Sincerely,

Jeffrey P. Koplan, M.D., M.P.H.
Director